Anthropic's Fable 5 model is once again available for use, the company said today. Claude users are now seeing the option to ...

Frontier model launches are starting to look less like ordinary product releases and more like negotiated deployments shaped by U.S. national security review.

The Trump administration reversed its shutdown order after weeks of talks, with Anthropic tying Fable 5's return to a new safety classifier and other moves.

Her work explores how new AI technology is infiltrating our lives, shaping the content we consume on social media and affecting the people behind the screens. She graduated from the University of ...

The US has lifted export curbs on Anthropic’s newest Claude models, Fable 5 and Mythos 5, about three weeks after the Trump ...

Anthropic is restoring Fable 5 and Mythos 5 access after the US lifted export controls tied to a cybersecurity jailbreak ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Today's NYT Connections puzzle for Wednesday, June 17 may have stumped you. If you are not ...

The U.S. government on Friday ordered Anthropic to immediately shut off access to two of its most powerful AI models — Claude Fable 5 and Claude Mythos 5 — citing national security concerns. Anthropic ...

During the WWDC26 keynote, Apple announced its third generation of Apple Foundation Models (AFM), comprising five models, some of which are local, some of which are cloud-based, and one of which lives ...

On June 9, Anthropic released Claude Fable 5, the most capable model it has ever made, generally available. It also did something unusual: it shipped one model as two products, split not by capability ...

Anthropic is bringing its most powerful AI model to the general public for the first time, but it’s doing it with guardrails. On Tuesday, the AI firm launched Claude Fable 5, the first publicly ...

Test time has arrived: the first person has been treated in a highly anticipated gene-therapy trial that aims to coax aged cells to take on a younger identity. The clinical trial is testing an ...